Scientific Presentations

ESMO Poster Phase II Trial of SM-88 in Non-Metastatic Biochemical Recurrent Prostate Cancer

ESMO Poster Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in Heavily Pre-Treated PDAC Patients

AACR Poster CTC-based Efficacy of SM-88 Correlates with Overall Survival in Advanced Pancreatic Cancer

AACR Poster Therapeutic Potential of Targeting Amino Acid Metabolism in Pancreatic Cancer

ESMO GI Poster SM-88 Therapy in High-Risk Poor Prognosis Pancreatic Cancer

ASCO GU Poster Evaluating Non-hormonal Therapy in a Phase II Trial of SM-88 for Rising PSA Prostate Cancer

ASCO GU Poster Typical Hormone Deprivation Side Effects Compared to SM-88 Therapy for Rising PSA

ASCO GI Poster Phase II Trial of SM-88 in Patients with Metastatic Pancreatic Cancer: Preliminary Results of the 1st Stage
Note: Replaced as of 1/18/19 10:43 AM ET.

ASCO GI Poster Phase II Pharmacokinetics of Oral SM-88 in Heavily Pretreated Advanced Pancreatic Ductal Adenocarcinoma (PC)

ASCO GI Poster Feasibility of SM-88 in PC After Multiple Prior Lines and ECOG ≤2 (NCT03512756)

ASCO GI Poster Designing Clinical Trials in 3L+ Pancreatic Cancer

ASCO General Meeting Poster TPS4156 SM-88 in Advanced Cancers of the Pancreas

ASCO General Abstract e13100 SM-88 Efficacy and Safety in Metastatic Breast Cancers

ASCO General Abstract e24072 Prospective Comparison of Invasive Circulating Tumor Cells (iCTCs) vs PSA and mPFS in Prostate Cancer (PC) Treated with SM-88

ASCO General Abstract e14535 SM-88 Efficacy Across Multiple High-Risk Factors

ASCO General Abstract e14528 Comparison of SUV and RECIST Responses in Cancers Treated with SM-88

ASCO GU Poster 2018 Phase II Trial of SM-88 in Non-Metastatic Biochemical Recurrent Prostate Cancer

ASCO GI Poster 2018 SM-88 Therapy in Patients with Advanced or Metastatic Pancreatic Cancer

ASCO 2017

ASCO Poster 2017 – A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TYME-88 (SM-88) in Patients with Prostate Cancer

A phase Ib/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer. Abstract: TPS2615

SMK/SM88 toxicity, efficacy, and patient-reported outcomes in metastatic pancreas cancer. Abstract: e14060

Phase Ib pharmacokinetics of non-hormonal SM88 in patients with non-metastatic recurrent prostate cancer. Abstract: E14061

SM88/SMK non-hormonal therapy in recurrent or untreated prostate cancer. Abstract: E16540

SM88 in non-metastatic rising PSA-recurrent prostate cancer. Abstract: E16567

ESMO 2017

ESMO 2017 SM-88 Poster. September 2017

ESMO 2016 Preclinical Data Poster. October 2016